This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accenture: Analysts' Upgrades, Downgrades


Accenture (ACN - Get Report) was upgraded to Outperform at Wells Fargo. Visibility is improving, and business fundamentals appear to have reached an inflection point.

Archer-Daniels Midland (ADM - Get Report) was downgraded to Market Perform at BMO Capital. Valuation call, based on a $36 price target.

Beacon Roofing (BECN - Get Report) was downgraded from Outperform to Neutral at Robert Baird. $16 price target. Shingle pricing has turned negative.

ConocoPhillips (COP - Get Report) was downgraded to Underweight at Morgan Stanley. Valuation call, based on a $56 price target.

Deere (DE - Get Report) was downgraded to Market Perform at Wells Fargo. Company is not likely to raise guidance above current consensus expectations.

Amdocs (DOX - Get Report) was started with a Hold rating at ThinkEquity. $30 price target. Future growth will most likely be driven by acquisitions.

Idacorp (IDA - Get Report) was upgraded from Hold to Buy at Keybanc. $38.50 price target. Two tax deductions will benefit equity value.

Limited Brands (LTD) was downgraded to Sell at Goldman Sachs. $24 price target. Company faces earnings headwinds in 2011.

Norfolk Southern (NSC) was downgraded to Market Perform at Wells Fargo. Valuation call, as coal demand could wane.

Rubicon Technology (RBCN) was initiated with a Sell rating at Merriman, Curhan Ford. Supply has caught up to demand in LCD lighting.

The Hanover Insurance Group (THG) was downgraded to Equal Weight from Overweight at Barclays. Less earnings power and reduced ROE improvement, Barclays said. Price target cut to $46 from $49.

Walgreen (WAG) was upgraded from Equal-Weight to Overweight at Morgan Stanley. $40 price target. Company faces easy comparisons for the flu season.

Wright Medical (WMGI) was downgraded from Outperform to Neutral at Robert Baird. $17 price target. Company could struggle to achieve consensus earnings expectations.

Xilinx (XLNX) was downgraded from Neutral to Sell at Goldman Sachs. Estimates were also cut, as cyclical pressures could hurt earnings. $22 price target.


Accenture 2011 and 2012 estimates boosted to $3.03 and $3.46, respectively, at Credit Suisse. Banking on enterprise spend recovery, Credit Suisse said. Maintain Outperform rating and $55 price target.

Accenture estimates, target increased at Citigroup. Estimates were raised through 2012. Company had a good quarter and boosted guidance. Buy rating and new $53 price target.

Altera (ALTR) estimates, target reduced at Goldman. Estimates were cut through 2012, Goldman Sachs said. Company faces cyclical headwinds. Neutral rating and new $26 price target.

Covance (CVD) estimates, target boosted at Jefferies. Shares now seen reaching $54, according to Jefferies. Estimates also upped, given the new $2.2 billion contract from SNY. Buy rating.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACN $114.08 0.47%
ADM $38.08 -1.65%
BECN $42.40 -0.33%
COP $43.21 -0.46%
DE $81.20 -1.19%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs